Successful management of transcatheter aortic valve implantation by platelet transfusions in a nonagenarian patient with severe autoimmune factor V deficiency
- 37 Downloads
The most common acquired inhibitors to coagulation factors, after factor VIII or von Willebrand factor, are directed against factor V (FV) [1, 2, 3]. Bleeding risk associated with FV inhibitors is highly variable with poor correlation to coagulation studies rendering this disease challenging to manage . Here, we report the successful management of a transcatheter aortic valve implantation (TAVI), using platelet concentrates, in a nonagenarian patient with severe FV inhibitors.
The patient was a 93-year-old woman who was hospitalized in an emergency situation due to acute congestive heart failure. The cause of heart disease included coronary artery diseases, atrial fibrillation, and severe aortic stenosis. During her hospitalization, she developed urinary tract infection treated by ceftriaxone.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Informed consent was obtained from the patient for being included in the study.
- 5.Auffret V, Lefevre T, Van Belle E, Eltchaninoff H, Iung B, Koning R, Motreff P, Leprince P, Verhoye JP, Manigold T, Souteyrand G, Boulmier D, Joly P, Pinaud F, Himbert D, Collet JP, Rioufol G, Ghostine S, Bar O, Dibie A (2017) Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol 70:42–55CrossRefGoogle Scholar
- 6.Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, Morfini M, Santagostino E, Rocino A (2015) Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus 13:498–513Google Scholar